Abstract
The aim of the present study was to evaluate the effects of two phospholipid permeation enhancers, lysophosphatidylcholine (LPC) and didecanoylphosphatidylcholine (DDPC), along with a fusidic acid derivative, sodium taurodihydrofusidate (STDHF) and ethanol (EtOH) on the buccal transport of propranolol hydrochloride (PPL) using anex vivo buccal diffusion model. The permeation rate of [3H]PPL as measured by steady-state fluxes increased with increasing EtOH concentration. A significant flux enhancement (P<0.05) was achieved by EtOH at 20 and 30 %v/v concentrations. At a 0.5 %w/v permeation enhancer concentration, the buccal permeation of [3H]PPL was significantly enhanced by all the enhancers studied (i.e., LPC, DDPC and STDHF) compared to the control (phosphate-buffered saline pH 7.4, PBS). LPC and DDPC displayed a greater degree of permeation enhancement compared with STDHF and EtOH-PBS mixtures with an enhancement ratio of 3.2 and 2.9 for LPC and DDPC, respectively compared with 2.0 and 1.5 for STDHF and EtOH:PBS 30:70 %v/v mixture, respectively. There was no significant difference between LPC and DDPC for the flux values and apparent permeability coefficients of [3H]PPL. These results suggest that phospholipids are suitable as permeation enhancers for the buccal delivery of drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anders, R. and Merkle, H. P., Evaluation of laminated muco- adhesive patches for buccal drug delivery.Int. J. Pharm., 49, 231–240 (1989).
Aungst, B. J., Rogers, N. J., and Shefter, E., Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter.J. Pharmacol. Exp. Ther., 24, 23–27 (1988).
Aungst, B. J. and Rogers, N. J., Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery.Int. J. Pharm., 53, 227–235 (1989).
Bolin, T., Franzen, L., Sjodahl, R., and Tagesson, C., Passage of molecules through the wall of the gastrointestinal tract.Scand. J. Gastroenterol., 21, 441–448 (1986).
Chidambaram, N. and Srivatsava, A. K., Buccal drug delivery systems.Drug Dev. Ind. Pharm., 21, 1009–1036 (1995).
Cid, E., Mella, R., Lucchini, L., Carcamo, M., and Monasterio, J., Plasma concentrations and bioavailability of propranolol by oral, rectal and intravenous administration in man.Biopharm. Drug Dispos., 7, 559–566 (1986).
Coutel-Egros, A., Maitani, Y., Veillard, M., Machida, Y., and Nagai, T., Combined effects of pH, cosolvent and penetration enhancers on thein vitro buccal absorption of propranolol through excised hamster cheek pouch.Int. J. Pharm., 84, 117–128 (1992).
DeGrande, G., Benes, L., Horriere, F., Karsenty, H., Lacoste, C., McQuinn, R., Gou, J.-H., and Scherrer, R., Specialized oral mucosal drug delivery systems: Patches, In Rathbone, M. J. (Eds.). Oral Mucosal Drug Delivery. Marcel Dekker, New York, pp. 285–317, (1996).
De Vries, M. E., Bodde, H. E., Verhoef, J. C., and Junginger, H. E., Developments in buccal drug delivery.Crit. Rev. Therap. Drug Can. Syst., 8, 271–303 (1991).
Dowty, M. E., Knuth, K. E., Irons, B. K., and Robinson, J. R., Transport of thyrotropin releasing hormone in rabbit buccal mucosain vitro.Pharm. Res., 9, 1113–1122 (1992).
Risher, A. N., Farraj, N. P., OHagan, D. T., Jabbal-Gill, I., Johansen, B. R., Davis, S. S., and Illum, L., Effect of L-α- lysophosphatidylcholine on the nasal absorption of human growth hormone in three animal species.Int. J. Pharm., 74, 147–156 (1991).
Ganem-Quintanar, A., Kalia, Y. N., Falson-Rieg, P., and Buri, P., Mechanism of oral permeation enhancement.Int. J. Pharm., 156, 127–142 (1997).
Harris, D. and Robinson, J. R., Drug delivery via the mucous membranes of the oral cavity.J. Pharm. Sci., 81, 1–10 (1992).
Hermens, W. A. J. J., Hooymans, P. M., Verhoef, J. C., and Merkus, R. W. H. M., Effects of absorption enhancers on human nasal tissue ciliary movement in vitro.Pharm. Res., 7, 144–146 (1990).
Hirai, S., Yashiki, T., and Mima, H., Effect of surfactants on the nasal absorption of insulin in rats.Int. J. Pharm., 9, 165–172 (1981).
Hovgaard, L., Brøndsted, H., and Nielsen, H. M., Drug delivery studies in Caco-2 monolayers. II. Absorption enhancer effects of lysophosphatidylcholines.Int. J. Pharm., 114, 141–149 (1995).
Iwamoto, K. and Watanabe, J., Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats.J. Pharm. Pharmacol., 37, 826–828 (1985).
Kissel, T., Drewe, J., Bantle, S., Rummelt, A., and Beglinger, C., Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects.Pharm. Res., 9, 52–57 (1992).
Le Brun, P. P. H., Fox, P. L. A., De Vries, M. E., and Boddé, H. E.,In vitro penetration of some β-adrenoreceptor blocking drugs through porcine buccal mucosa.Int. J. Pharm., 49, 141–145 (1989).
Lee, J. and Kellaway, I. W., Buccal permeation of [D-Ala2, D-Leu5]enkephalin from liquid crystalline phases of glyceryl monooleate.Int. J. Pharm., 195, 35–38 (2000).
Lee, J., Lee, S. K., and Choi, Y. W., The effect of storage conditions on the permeability of porcine buccal mucosa.Arch. Pharm. Res., 25, 546–549 (2002).
Parfitt, K., Martindale (32nd edition). Pharmaceutical Press, London, (1999).
Richardson, J. L., Minhas, P. S., Thomas, N. W., and Illum, L., Vaginal administration of gentamicin to rats. Pharmaceutical and morphological studies using absorption enhancers.Int. J. Pharm., 56, 29–35 (1989).
Schürmann, W. and Turner, P., A membrane model of the human oral mucosa as derived from buccal absorption performance and physicochemical properties of the β-blocking drugs atenolol and propranolol.J. Pharm. Pharmacol., 30, 137–147 (1978).
Senel, S. and Hincal, A. A., Drug permeation enhancement via buccal route: possibilities and limitations.J. Control. Rel., 72, 133–144 (2001).
Shand, D. G., Nickolis, E. M., and Oates, J. A., Plasma propranolol levels in adults with observation in four children.Clin. Pharmacol. Ther, 11, 112–118 (1970).
Vermehren, C. and Hansen, H. S., Shape changes in the erythrocyte membrane induced by the absorption enhancer didecanoylphosphatidylcholine.Int. J. Pharm., 174, 1–8 (1998).
Walle, T., Conradi, E. C., Walle, U. K., Pagan, T. C., and Gaffney, T. E., The predictable relationship between plasma levels and dose during chronic propranolol therapy.Clin. Pharmacol. Ther., 24, 668–677 (1978).
Wertz, P. W. and Squier, C. A., Cellular and molecular basis of barrier function in oral epithelium.Crit. Rev. Therap. Drug Carr. Syst, 8, 237–269 (1991).
Zhang, J., Niu, S., Ebert, C., and Stanley, T. H., Anin vivo dog model for studying recovery kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage.Int. J. Pharm., 101, 15–22 (1994).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, J., Choi, Y.W. Enhancedex vivo buccal transport of propranolol: Evaluation of phospholipids as permeation enhancers. Arch Pharm Res 26, 421–425 (2003). https://doi.org/10.1007/BF02976701
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02976701